×

AveXis to Report Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1

-- Jerry Mendell, M.D., to Present Data as of April 1, 2016 at the American Society of Gene & Cell Therapy 19th Annual Meeting --

-- Company to Host Webcast on Friday, May 6, 2016 at 4:30 p.m. Eastern Daylight Time --

CHICAGO, April 25, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced Jerry Mendell, M.D., director of the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital, will present data as of April 1, 2016 from the ongoing Phase 1 clinical trial of AVXS-101 in Spinal Muscular Atrophy (SMA) Type 1 during the American Society of Gene & Cell Therapy’s 19th Annual Meeting. The data will be presented during the Presidential Symposium on Friday, May 6, 2016 at 3:10 p.m. Eastern Daylight Time (EDT).

AveXis will host a live webcast briefing following the presentation at 4:30 p.m. EDT. Analysts and investors can participate in the conference call by dialing (877) 508-0547 for domestic callers and (615) 247-5963 for international callers, using the conference ID 95576133. The webcast can be accessed live on the Events and Presentations page in the Investors and Media section of the AveXis website, www.AveXis.com. The webcast will be archived on the company’s website for 30 days and will be available for telephonic replay for 14 days following the call by dialing (855) 859-2056 (Domestic) or (404) 537-3406 (International), conference ID 95576133.

About SMA
SMA is a severe neuromuscular disease characterized by the loss of motor neurons leading to progressive muscle weakness and paralysis. SMA is caused by a genetic defect in the SMN1 gene that codes SMN, a protein necessary for survival of motor neurons. The incidence of SMA is approximately one in 10,000 live births.

The most severe form of SMA is Type 1, a genetic disorder characterized by motor neuron loss and associated muscle deterioration, which results in mortality or the need for permanent ventilation support before the age of two for greater than 90 percent of patients. SMA Type 1 is the leading genetic cause of infant mortality.

About AveXis, Inc.
AveXis is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company’s initial proprietary gene therapy candidate, AVXS-101, is in an ongoing Phase 1 clinical trial for the treatment of SMA Type 1. For additional information, please visit www.avexis.com.

Media Inquiries: Lauren Barbiero W2O Group 646-564-2156 lbarbiero@w2ogroup.com Investor Inquiries: Jim Goff AveXis, Inc. 650-862-4134 jgoff@avexis.com

Source:AveXis